EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors

Ankit Kumar Singh, Adarsh Kumar, Sahil Arora, Raj Kumar, Amita Verma, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas, Pradeep Kumar iD

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14372 ↗

At a glance

Übersichtsarbeit in Chemical Biology & Drug Design, 2024. Written by Ankit Kumar Singh and 8 co-authors. Institution: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India. Major MEDLINE topics: Anti-HIV Agents, HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome. Cited 22 times so far (Crossref); 116 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, 38.4 million people worldwide were living with HIV in 2021. Viral reverse transcriptase (RT) is an excellent target for drug intervention. Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of approved antiretroviral drugs. Later, a new type of non‐nucleoside reverse transcriptase inhibitors (NNRTIs) were approved as anti‐HIV drugs. Zidovudine, didanosine, and stavudine are FDA‐approved NRTIs, while nevirapine, efavirenz, and delavirdine are FDA‐approved NNRTIs. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine. This review addresses HIV‐1 structure, replication cycle, reverse transcription, and HIV drug targets. This study focuses on NRTIs and NNRTIs, their binding sites, mechanisms of action, FDA‐approved drugs and drugs in clinical trials, their resistance and adverse effects, their molecular docking studies, and highly active antiretroviral therapy (HAART).

Subjects

MeSH terms (MEDLINE)

Anti-HIV AgentsHIV-1HIV InfectionsAcquired Immunodeficiency SyndromeHumansReverse Transcriptase InhibitorsMolecular Docking SimulationHIV Reverse Transcriptase

Author keywords

AIDSHAARTHIVNNRTINRTIRT

Substances

Reverse Transcriptase InhibitorsAnti-HIV AgentsHIV Reverse Transcriptase

Authors and institutions

  • Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India.
  • Department of Pharmaceutical Sciences, Bioorganic and Medicinal Chemistry Research Laboratory, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, Uttar Pradesh, India.
  • Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unayzah, Saudi Arabia.
  • Smart-Health Initiative (SHI) and Red Sea Research Center (RSRC), Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabi…
  • Core Labs, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.

ORCID profiles: Pradeep Kumar

Cite

APA

Singh, A. K., Kumar, A., Arora, S., Kumar, R., Verma, A., Khalilullah, H., Jaremko, M., Emwas, A. H., & Kumar, P. (2024). Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14372

Vancouver

Singh AK, Kumar A, Arora S, Kumar R, Verma A, Khalilullah H, et al. Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14372

BibTeX
@article{Singh2024,
  author = {Singh, Ankit Kumar and Kumar, Adarsh and Arora, Sahil and Kumar, Raj and Verma, Amita and Khalilullah, Habibullah and Jaremko, Mariusz and Emwas, Abdul-Hamid and Kumar, Pradeep},
  title = {Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14372}
}
Start for free →